DiCE Molecules is a biotechnology company utilizing its proprietary DNA-encoded library (DEL) technology, combined with unique structural insights, to generate small molecule antagonists against a range of protein-protein-interface (PPI) targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/21 | $80,000,000 | Series C |
Alexandria Venture Investments Altitude Life Sciences Ventures Asymmetry Capital Management Driehaus Capital Management Eventide Asset Management New Leaf Venture Partners Northpond Ventures Osage University Partners RA Capital Management  Sands Capital Sanofi Ventures Soleus Capital | undisclosed |
